Patents by Inventor Chong-xian Pan
Chong-xian Pan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11474106Abstract: The invention relates to methods, systems and kits for determining therapeutic effectiveness or toxicity of cancer-treating compounds that incorporate into or bind to DNA. In particular, the invention is directed to methods, systems and kits for predicting a patient's treatment outcome after administration of a microdose of therapeutic composition to the patient. The methods provides physicians with a diagnostic tool to segregate cancer patients into differential populations that have a higher or lower chance of responding to a particular therapeutic treatment.Type: GrantFiled: July 7, 2016Date of Patent: October 18, 2022Assignee: LAWRENCE LIVERMORE NATIONAL SECURITY, LLCInventors: Paul Henderson, George D. Cimino, Chong-Xian Pan, Ralph William de Vere White, Maike Zimmermann, Kenneth W. Turteltaub
-
Patent number: 11426385Abstract: Provided are methods and compositions for prolonging survival and/or reducing or inhibiting tumor growth in a cancer subject receiving a regimen of one or more chemotherapeutic agents, an inhibitor of soluble epoxide hydrolase (sEHi) and a non-steroidal anti-inflammatory drug (NSAID) that inhibits one or more enzymes selected from the group consisting of cyclo-oxygenase (“COX”)-1, COX-2, and 5-lipoxygenase (“5-LOX”). The methods and compositions decrease toxicity and/or adverse side effects in subjects receiving a regimen of one or more chemotherapeutic agents.Type: GrantFiled: August 14, 2018Date of Patent: August 30, 2022Assignees: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, United States as represented by the Department of Veterans AffairsInventors: Bruce D. Hammock, Sung Hee Hwang, Ralph W. de Vere White, Chong-xian Pan, Hongyong Zhang, Paul Henderson, Ai-Hong Ma, Maike Zimmermann, Fuli Wang
-
Patent number: 11219692Abstract: The present invention provides amphiphilic telodendrimers that aggregate to form nanocarriers characterized by a hydrophobic core and a hydrophilic exterior. The nanocarrier core may include amphiphilic functionality such as cholic acid or cholic acid derivatives, and the exterior may include branched or linear poly(ethylene glycol) segments. Nanocarrier cargo such as hydrophobic drugs and other materials may be sequester in the core via non-covalent means or may be covalently bound to the telodendrimer building blocks. Telodendrimer structure may be tailored to alter loading properties, interactions with materials such as biological membranes, and other characteristics.Type: GrantFiled: March 15, 2019Date of Patent: January 11, 2022Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Kit S. Lam, Yuanpei Li, Chong-Xian Pan
-
Patent number: 11215617Abstract: The present invention provides new compositions and methods for treating prostate cancer, e.g., drug-resistant prostate cancer, such as anti-androgen drug (e.g., enzalutamide) resistant and/or castration resistant prostate cancer (CRPC). These new compositions include, but are not limited to, pharmaceutical compositions that include an AR-V7 inhibitor, such as niclosamide. Alternatively, these new compositions can include, but are not limited to, pharmaceutical compositions that include an AKR1C3 inhibitor, such as indomethacin. These new methods include, but are not limited to, methods of administering an AR-V7 inhibitor, such as niclosamide, and/or an AKR1C3 inhibitor, such as indomethacin, to treat patients having prostate cancer. The present invention also provides methods of inhibiting androgen receptor variant expression, e.g. AR-V7, and methods of killing cells expressing AR-V7.Type: GrantFiled: October 16, 2019Date of Patent: January 4, 2022Assignees: The Regents of the University of California, U.S. Government Represented by the Department of Veterans AffairsInventors: Allen C. Gao, Chengfei Liu, Wei Lou, Chong-xian Pan
-
Publication number: 20200197368Abstract: Provided are methods and compositions for prolonging survival and/or reducing or inhibiting tumor growth in a cancer subject receiving a regimen of one or more chemotherapeutic agents, an inhibitor of soluble epoxide hydrolase (sEHi) and a non-steroidal anti-inflammatory drug (NSAID) that inhibits one or more enzymes selected from the group consisting of cyclo-oxygenase (“COX”)-1, COX-2, and 5-lipoxygenase (“5-LOX”). The methods and compositions decrease toxicity and/or adverse side effects in subjects receiving a regimen of one or more chemotherapeutic agents.Type: ApplicationFiled: August 14, 2018Publication date: June 25, 2020Inventors: Bruce D. HAMMOCK, Sung Hee HWANG, Ralph W. de VERE WHITE, Chong-xian PAN, Hongyong ZHANG, Paul HENDERSON, Ai-Hong MA, Maike ZIMMERMAN, Fuli WANG
-
Publication number: 20200046841Abstract: The present invention provides amphiphilic telodendrimers that aggregate to form nanocarriers characterized by a hydrophobic core and a hydrophilic exterior. The nanocarrier core may include amphiphilic functionality such as cholic acid or cholic acid derivatives, and the exterior may include branched or linear poly(ethylene glycol) segments. Nanocarrier cargo such as hydrophobic drugs and other materials may be sequester in the core via non-covalent means or may be covalently bound to the telodendrimer building blocks. Telodendrimer structure may be tailored to alter loading properties, interactions with materials such as biological membranes, and other characteristics.Type: ApplicationFiled: March 15, 2019Publication date: February 13, 2020Inventors: Kit S. LAM, Yuanpei LI, Chong-Xian PAN
-
Publication number: 20200041516Abstract: The present invention provides new compositions and methods for treating prostate cancer, e.g., drug-resistant prostate cancer, such as anti-androgen drug (e.g., enzalutamide) resistant and/or castration resistant prostate cancer (CRPC). These new compositions include, but are not limited to, pharmaceutical compositions that include an AR-V7 inhibitor, such as niclosamide. Alternatively, these new compositions can include, but are not limited to, pharmaceutical compositions that include an AKR1C3 inhibitor, such as indomethacin. These new methods include, but are not limited to, methods of administering an AR-V7 inhibitor, such as niclosamide, and/or an AKR1C3 inhibitor, such as indomethacin, to treat patients having prostate cancer. The present invention also provides methods of inhibiting androgen receptor variant expression, e.g. AR-V7, and methods of killing cells expressing AR-V7.Type: ApplicationFiled: October 16, 2019Publication date: February 6, 2020Applicants: The Regents of the University of California, U.S. Government represented by the Department of Veterans AffairsInventors: Allen C. Gao, Chengfei Liu, Wei Lou, Chong-xian Pan
-
Publication number: 20200010910Abstract: The invention relates to methods, systems and kits for determining therapeutic effectiveness or toxicity of cancer-treating compounds that incorporate into or bind to DNA. In particular, the invention is directed to methods, systems and kits for predicting a patient's treatment outcome after administration of a microdose of therapeutic composition to the patient or a sample from the patient. The methods provides physicians with a diagnostic tool to segregate cancer patients into differential populations that have a higher or lower chance of responding to a particular therapeutic treatment.Type: ApplicationFiled: July 10, 2019Publication date: January 9, 2020Inventors: Paul Henderson, George D. Cimino, Maike Zimmermann, Michael A. Malfatti, Kenneth W. Turteltaub, Ralph W. De Vere White, Brian Jonas, Tiffany Scharadin, Chong-Xian Pan
-
Patent number: 10335365Abstract: The present invention is directed to bladder cancer specific ligand peptides, comprising the amino acid sequence X1DGRX5GF (SEQ ID NO: 1), and methods of their use, e.g., for imaging detection for diagnosis of bladder, tumor localization to guide transurethral resection of bladder cancer, imaging detection of bladder cancer for follow-up after the initial treatment that can replace or complement costly cystoscopy, imaging detection of metastatic bladder cancer, and targeted therapy for superficial and metastatic bladder cancer.Type: GrantFiled: January 7, 2017Date of Patent: July 2, 2019Assignees: The Regents ot the Univershy of California, The United States of America as represented by the Department of Veteran Affairs (Washington DC)Inventors: Chong-Xian Pan, Hongyong Zhang, Kit S. Lam, Olulanu H. Aina
-
Patent number: 10100083Abstract: The present invention is directed to C-type lectin-like molecule-1 (CLL1) specific ligand peptides, comprising the amino acid motif LR(S/T), and methods of their use, e.g., for imaging detection for diagnosis of leukemia and the presence of leukemic stem cells (LSCs) and targeted therapy against leukemia mediated at least in part by CLL1-expressing LSCs.Type: GrantFiled: April 29, 2016Date of Patent: October 16, 2018Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Chong-xian Pan, Hongyong Zhang
-
Publication number: 20180209984Abstract: The invention relates to methods, systems and kits for determining therapeutic effectiveness or toxicity of cancer-treating compounds that incorporate into or bind to DNA. In particular, the invention is directed to methods, systems and kits for predicting a patient's treatment outcome after administration of a microdose of therapeutic composition to the patient. The methods provides physicians with a diagnostic tool to segregate cancer patients into differential populations that have a higher or lower chance of responding to a particular therapeutic treatment.Type: ApplicationFiled: July 7, 2016Publication date: July 26, 2018Inventors: Paul Henderson, George D. Cimino, Chong-Xian Pan, Ralph William de Vere White, Maike Zimmermann, Kenneth W. Turteltaub
-
Publication number: 20180036417Abstract: The present invention provides amphiphilic telodendrimers that aggregate to form nanocarriers characterized by a hydrophobic core and a hydrophilic exterior. The nanocarrier core may include amphiphilic functionality such as cholic acid or cholic acid derivatives, and the exterior may include branched or linear poly(ethylene glycol) segments. Nanocarrier cargo such as hydrophobic drugs and other materials may be sequester in the core via non-covalent means or may be covalently bound to the telodendrimer building blocks. Telodendrimer structure may be tailored to alter loading properties, interactions with materials such as biological membranes, and other characteristics.Type: ApplicationFiled: March 24, 2017Publication date: February 8, 2018Inventors: Kit S. LAM, Yuanpei LI, Chong-Xian PAN, Tzu-yin LIN
-
Publication number: 20170315127Abstract: The present invention provides new compositions and methods for treating prostate cancer, e.g., drug-resistant prostate cancer, such as anti-androgen drug (e.g., enzalutamide) resistant and/or castration resistant prostate cancer (CRPC). These new compositions include, but are not limited to, pharmaceutical compositions that include an AR-V7 inhibitor, such as niclosamide. Alternatively, these new compositions can include, but are not limited to, pharmaceutical compositions that include an AKR1C3 inhibitor, such as indomethacin. These new methods include, but are not limited to, methods of administering an AR-V7 inhibitor, such as niclosamide, and/or an AKR1C3 inhibitor, such as indomethacin, to treat patients having prostate cancer. The present invention also provides methods of inhibiting androgen receptor variant expression, e.g. AR-V7, and methods of killing cells expressing AR-V7.Type: ApplicationFiled: April 20, 2016Publication date: November 2, 2017Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: ALLEN C. GAO, CHENGFEI LIU, WEI LOU, Chong-xian Pan
-
Publication number: 20170173174Abstract: The present invention is directed to bladder cancer specific ligand peptides, comprising the amino acid sequence X1DGRX5GF (SEQ ID NO: 1), and methods of their use, e.g., for imaging detection for diagnosis of bladder, tumor localization to guide transurethral resection of bladder cancer, imaging detection of bladder cancer for follow-up after the initial treatment that can replace or complement costly cystoscopy, imaging detection of metastatic bladder cancer, and targeted therapy for superficial and metastatic bladder cancer.Type: ApplicationFiled: January 7, 2017Publication date: June 22, 2017Applicant: The Regents of the University of CaliforniaInventors: Chong-Xian PAN, Hongyong ZHANG, Kit S. LAM, Olulanu H. AINA
-
Patent number: 9642916Abstract: The present invention provides amphiphilic telodendrimers that aggregate to form nanocarriers characterized by a hydrophobic core and a hydrophilic exterior. The nanocarrier core may include amphiphilic functionality such as cholic acid or cholic acid derivatives, and the exterior may include branched or linear poly(ethylene glycol) segments. Nanocarrier cargo such as hydrophobic drugs and other materials may be sequester in the core via non-covalent means or may be covalently bound to the telodendrimer building blocks. Telodendrimer structure may be tailored to alter loading properties, interactions with materials such as biological membranes, and other characteristics.Type: GrantFiled: March 14, 2013Date of Patent: May 9, 2017Assignee: The Regents of the University of CaliforniaInventors: Kit S. Lam, Yuanpei Li, Chong-Xian Pan, Tzu-yin Lin
-
Patent number: 9539340Abstract: The present invention is directed to bladder cancer specific ligand peptides, comprising the amino acid sequence X1DGRX5GF (SEQ ID NO:1), and methods of their use, e.g., for imaging detection for diagnosis of bladder, tumor localization to guide transurethral resection of bladder cancer, imaging detection of bladder cancer for follow-up after the initial treatment that can replace or complement costly cystoscopy, imaging detection of metastatic bladder cancer, and targeted therapy for superficial and metastatic bladder cancer.Type: GrantFiled: January 5, 2015Date of Patent: January 10, 2017Assignee: The Regents of the University of CaliforniaInventors: Chong-Xian Pan, Hongyong Zhang, Kit S. Lam, Olulanu H. Aina
-
Publication number: 20160237118Abstract: The present invention is directed to C-type lectin-like molecule-1 (CLL1) specific ligand peptides, comprising the amino acid motif LR(S/T), and methods of their use, e.g., for imaging detection for diagnosis of leukemia and the presence of leukemic stem cells (LSCs) and targeted therapy against leukemia mediated at least in part by CLL1-expressing LSCs.Type: ApplicationFiled: April 29, 2016Publication date: August 18, 2016Applicant: The Regents of the University of CaliforniaInventors: Chong-xian PAN, Hongyong ZHANG
-
Patent number: 9334306Abstract: The present invention is directed to C-type lectin-like molecule-1 (CLL1) specific ligand peptides, comprising the amino acid motif LR(S/T), and methods of their use, e.g., for imaging detection for diagnosis of leukemia and the presence of leukemic stem cells (LSCs) and targeted therapy against leukemia mediated at least in part by CLL1-expressing LSCs.Type: GrantFiled: July 9, 2012Date of Patent: May 10, 2016Assignee: The Regents of the University of CaliforniaInventors: Chong-xian Pan, Hongyong Zhang
-
Publication number: 20150190527Abstract: The present invention is directed to bladder cancer specific ligand peptides, comprising the amino acid sequence X1DGRX5GF (SEQ ID NO:1), and methods of their use, e.g., for imaging detection for diagnosis of bladder, tumor localization to guide transurethral resection of bladder cancer, imaging detection of bladder cancer for follow-up after the initial treatment that can replace or complement costly cystoscopy, imaging detection of metastatic bladder cancer, and targeted therapy for superficial and metastatic bladder cancer.Type: ApplicationFiled: January 5, 2015Publication date: July 9, 2015Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Chong-Xian PAN, Hongyong ZHANG, Kit S. LAM, Olulanu H. AINA
-
Patent number: 8946379Abstract: The present invention is directed to bladder cancer specific ligand peptides, comprising the amino acid sequence X1DGRX5GF (SEQ ID NO:1), and methods of their use, e.g., for imaging detection for diagnosis of bladder, tumor localization to guide transurethral resection of bladder cancer, imaging detection of bladder cancer for follow-up after the initial treatment that can replace or complement costly cystoscopy, imaging detection of metastatic bladder cancer, and targeted therapy for superficial and metastatic bladder cancer.Type: GrantFiled: September 23, 2010Date of Patent: February 3, 2015Assignee: The Regents of the University of CaliforniaInventors: Chong-xian Pan, Hongyong Zhang, Kit S. Lam, Olulanu H. Aina